← Leaderboards
John Paderi John Paderi John Paderi
Ihp Therapeutics, Inc.
$6,183,017
Attributed
$6,183,017
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4M · FY2023–25$5M$3.8M$2.5M$1.3M$0
'23
'24
'25
Funding mix
By agency
NIH$6,183,017 · 3
By mechanism
R44$2,611,866 · 1
UG3$2,589,070 · 1
UH3$982,081 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Early Intervention”
- Suma Babu · Massachusetts General Hospital$11,004,714
- Sabrina Paganoni · Massachusetts General Hospital$11,004,714
- Robert C Alexander · Banner Health$8,197,111
- Matthew Morrow Engelhard · Duke University$7,519,665
- Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research$7,024,010
- Sunni L. Mumford · University Of Pennsylvania$6,439,627
Research focus
Early InterventionEventComplement InactivatorsDoseEffective TherapyEndotheliumCell AdhesionComplementComplexDesignCellsClinical DevelopmentChronicEmpowermentAcuteCanis FamiliarisAffectBindingBiologicalCaringCytolysisBloodAcute Pain ManagementFeedback
Grant awards (5)
A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease$982,081
UH3 · FY2025 · NS · contact PI
Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease$1,192,753
R44 · FY2024 · HL · contact PI
A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease$2,589,070
UG3 · FY2023 · NS · contact PI
Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease$1,117,633
R44 · FY2023 · HL · contact PI
Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease$301,480
R44 · FY2023 · HL · contact PI